2023 Q4 Form 10-Q Financial Statement

#000162828023036375 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $156.0K $141.0K
YoY Change 21.88% 51.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.725M $2.939M
YoY Change -11.47% -4.48%
% of Gross Profit
Research & Development $7.763M $8.022M
YoY Change 20.51% 33.5%
% of Gross Profit
Depreciation & Amortization $103.0K $110.0K
YoY Change 19.77% 35.8%
% of Gross Profit
Operating Expenses $10.49M $10.96M
YoY Change 10.17% 20.64%
Operating Profit -$10.82M
YoY Change 20.32%
Interest Expense $1.008M $1.070M
YoY Change 36.22% 133.62%
% of Operating Profit
Other Income/Expense, Net -$13.00K $1.089M
YoY Change -71.11% 158.06%
Pretax Income -$9.337M -$9.730M
YoY Change 7.36% 13.52%
Income Tax
% Of Pretax Income
Net Earnings -$9.343M -$9.731M
YoY Change 7.35% 13.53%
Net Earnings / Revenue -5989.1% -6901.42%
Basic Earnings Per Share -$0.22
Diluted Earnings Per Share -$0.21 -$0.22
COMMON SHARES
Basic Shares Outstanding 44.68M shares 44.68M shares
Diluted Shares Outstanding 44.68M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.96M $52.94M
YoY Change -52.17% -50.62%
Cash & Equivalents $21.66M $15.23M
Short-Term Investments $26.31M $37.71M
Other Short-Term Assets $2.301M $2.300M
YoY Change -56.14% -52.1%
Inventory
Prepaid Expenses $2.301M $2.344M
Receivables $288.0K $198.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $77.41M $83.91M
YoY Change -30.44% -29.94%
LONG-TERM ASSETS
Property, Plant & Equipment $1.238M $1.317M
YoY Change -2.44% 1.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.279M $1.387M
YoY Change -7.79% 653.8%
Total Long-Term Assets $4.225M $4.547M
YoY Change -13.9% 17.31%
TOTAL ASSETS
Total Short-Term Assets $77.41M $83.91M
Total Long-Term Assets $4.225M $4.547M
Total Assets $81.64M $88.45M
YoY Change -29.74% -28.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.966M $2.179M
YoY Change 0.51% 52.91%
Accrued Expenses $7.783M $6.151M
YoY Change 50.34% 0.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.44M $9.018M
YoY Change 33.71% 9.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.458M $1.600M
YoY Change -28.53% -26.4%
Total Long-Term Liabilities $1.458M $1.600M
YoY Change -28.53% -26.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.44M $9.018M
Total Long-Term Liabilities $1.458M $1.600M
Total Liabilities $11.90M $10.63M
YoY Change 20.82% 1.98%
SHAREHOLDERS EQUITY
Retained Earnings -$339.5M -$330.2M
YoY Change 13.9% 13.93%
Common Stock $4.000K $4.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $69.74M $77.83M
YoY Change
Total Liabilities & Shareholders Equity $81.64M $88.45M
YoY Change -29.74% -28.45%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$9.343M -$9.731M
YoY Change 7.35% 13.53%
Depreciation, Depletion And Amortization $103.0K $110.0K
YoY Change 19.77% 35.8%
Cash From Operating Activities -$7.139M -$7.960M
YoY Change -23.97% 6.33%
INVESTING ACTIVITIES
Capital Expenditures $8.000K $310.0K
YoY Change -89.33% -169.2%
Acquisitions
YoY Change
Other Investing Activities $13.57M $4.140M
YoY Change 91.25% -26.22%
Cash From Investing Activities $13.56M $3.820M
YoY Change 93.18% -26.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -7.139M -7.960M
Cash From Investing Activities 13.56M 3.820M
Cash From Financing Activities 0.000 0.000
Net Change In Cash 6.422M -4.140M
YoY Change -370.97% 84.16%
FREE CASH FLOW
Cash From Operating Activities -$7.139M -$7.960M
Capital Expenditures $8.000K $310.0K
Free Cash Flow -$7.147M -$8.270M
YoY Change -24.49% 17.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44677169 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
dei Entity Central Index Key
EntityCentralIndexKey
0001213037
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44677000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2023Q3 us-gaap Interest Income Operating
InterestIncomeOperating
1068000 usd
CY2022Q3 us-gaap Interest Income Operating
InterestIncomeOperating
458000 usd
us-gaap Interest Income Operating
InterestIncomeOperating
3061000 usd
us-gaap Interest Income Operating
InterestIncomeOperating
841000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44677000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44677000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43333000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43333000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44677000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44677000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43291000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43291000 shares
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1064000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
319000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11223000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
96503000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1581000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-355000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11150000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
86579000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
955000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-1000 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 usd
CY2022Q1 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
139000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-10993000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
130102000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1055000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-234000 usd
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10443000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
120474000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1037000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
203000 usd
CY2022Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8571000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
113212000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32104000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30007000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
295000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
150000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3600000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3244000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
716000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-672000 usd
crdf Release Of Clinical Trial Funding Commitment For Services Received
ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
0 usd
crdf Release Of Clinical Trial Funding Commitment For Services Received
ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
139000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-55000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-573000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
115000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3188000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4000 usd
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-408000 usd
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-408000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1428000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1325000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-420000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-271000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-34000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23748000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24430000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
574000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
931000 usd
us-gaap Proceeds From Insurance Settlement Investing Activities
ProceedsFromInsuranceSettlementInvestingActivities
0 usd
us-gaap Proceeds From Insurance Settlement Investing Activities
ProceedsFromInsuranceSettlementInvestingActivities
114000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
80534000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
61229000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
67491000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
80428000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
10165000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
51145000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22634000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31129000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1114000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6774000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16347000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11943000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15233000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18717000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
255000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
89315000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
20000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
415000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88920000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
81400000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9461252 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10934858 shares
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
37778000 usd
CY2023Q3 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
6000 usd
CY2023Q3 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
78000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
37706000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
28759000 usd
CY2023Q3 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
3000 usd
CY2023Q3 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
338000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
28424000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
66537000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
416000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
66130000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
84299000 usd
CY2022Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
19000 usd
CY2022Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
394000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
83924000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
5016000 usd
CY2022Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
1000 usd
CY2022Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
21000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4996000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4981000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4682000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3664000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3413000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1317000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1269000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2455000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1849000 usd
CY2023Q3 crdf Accrued Clinical Trial
AccruedClinicalTrial
2878000 usd
CY2022Q4 crdf Accrued Clinical Trial
AccruedClinicalTrial
2333000 usd
CY2023Q3 crdf Accrued Research Agreements
AccruedResearchAgreements
591000 usd
CY2022Q4 crdf Accrued Research Agreements
AccruedResearchAgreements
509000 usd
CY2023Q3 crdf Accrued Director Fees
AccruedDirectorFees
125000 usd
CY2022Q4 crdf Accrued Director Fees
AccruedDirectorFees
125000 usd
CY2023Q3 crdf Patent License And Other Fees Payable
PatentLicenseAndOtherFeesPayable
33000 usd
CY2022Q4 crdf Patent License And Other Fees Payable
PatentLicenseAndOtherFeesPayable
24000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
69000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
337000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6151000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5177000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
955000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1037000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3600000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3244000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4000000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4000000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3150000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
5150000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3150000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
600000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4360968 shares
CY2022Q4 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
5.33
crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P2Y1M6D
CY2023Q3 crdf Class Of Warrant Or Right Expired During Period
ClassOfWarrantOrRightExpiredDuringPeriod
1553020 shares
CY2023Q3 crdf Class Of Warrant Or Right Weighted Average Exercise Price Expired During Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod
10.54
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2807948 shares
CY2023Q3 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
2.45
crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P2Y2M12D
CY2022Q3 crdf Collaborative Arrangement Rights And Obligations Milestone And Royalty Payments Made
CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade
0 usd
CY2023Q3 crdf Collaborative Arrangement Rights And Obligations Milestone And Royalty Payments Made
CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade
0 usd

Files In Submission

Name View Source Status
crdf-20230930_pre.xml Edgar Link unprocessable
0001628280-23-036375-index-headers.html Edgar Link pending
0001628280-23-036375-index.html Edgar Link pending
0001628280-23-036375.txt Edgar Link pending
0001628280-23-036375-xbrl.zip Edgar Link pending
crdf-093023exhibit311.htm Edgar Link pending
crdf-093023exhibit312.htm Edgar Link pending
crdf-093023exhibit321.htm Edgar Link pending
crdf-093023exhibit322.htm Edgar Link pending
crdf-20230930.htm Edgar Link pending
crdf-20230930.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
crdf-20230930_def.xml Edgar Link unprocessable
crdf-20230930_lab.xml Edgar Link unprocessable
crdf-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
crdf-20230930_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending